PARP inhibitors in the treatment of triple-negative breast cancer. Clin Pharmacokinet. 2018;57:427-37.Geenen, J.J.J.; Linn, S.C.; Beijnen, J.H.; Schellens, J.H.M. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin. Pharmacokinet. 2017, 1-11. [CrossRef] [...
3.A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437–47. https:// doi. org/ 10. 1093/ annonc/mdz192. 4.Hyaluronic acid-coated and OLAparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negat...
[10] Tutt A,Garber JE,Kaufman B,et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer [J]. N Engl J Med,2021,384(25):2394-2405. [11] Abraham JE, Pinilla K, Dayimu A, et al. The PARTNER ...
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 2003, 302(5645): 643-646. 7. Ashworth A. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J ...
6.Marzio, A.; Puccini, J.; Kwon, Y.; Maverakis, N.K.; Arbini, A.; Sung, P.; Bar-Sagi, D.; Pagano, M. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Mol. Cell 2019, 73, 224–237.e226. ...
Introduction: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer, with limited targeted treatment options. TNBC patients can, however, benefit from targeted drugs known as Poly (ADP-Ribose) Polymerase inhibitors (PARPi). PARPi disrupt DNA repair pathways by targeting...
2.Lyons TG,Robson ME.Resurrection of PARP Inhibitors in Breast Cancer. J Natl Compr Canc Netw.2018 16(9):1150-1156. 3.S Vinayak, SM Tolaney, LS Schwartzberg, et al. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC),...
Triple-negative breast cancer (TNBC) is a particularly aggressive breast cancer subtype, characterised by a higher incidence in younger women, rapid metastasis, and a generally poor prognosis. Patients with TNBC and BRCA mutations face additional therape
“A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.”Oncotarget (2018). 3.Rodler, Eve Therese et al. “Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative ...
6.Marzio, A.; Puccini, J.; Kwon, Y.; Maverakis, N.K.; Arbini, A.; Sung, P.; Bar-Sagi, D.; Pagano, M. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Mol. Cell 2019, 73, 224–237.e226. ...